Endocrinology Medical News about Octreotide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

From somatostatin to octreotide LAR: evolution of a somatostatin analogue
Current Medical Research and Opinion, 11/06/09

Anthony L et al. – Octreotide is a potent synthetic somatostatin analogue that has become the mainstay of medical therapy for tumor control in neuroendocrine disorders such as acromegaly and GEP–NETs. The development of octreotide LAR offered a further advancement; less frequent dosing provided valuable benefits in quality of life to patients, with equivalent efficacy and tolerability. Moreover, recent results from the PROMID study have confirmed the antiproliferative effect of octreotide LAR in patients with well–differentiated metastatic GEP–NETs of the midgut. New therapeutic uses of octreotide are currently under investigation in a variety of clinical settings.

<< Previous
FDA Approves Revisions to Prescribing Information for Diabetes...

Next >>
Safety, tolerability, pharmacokinetics and pharmacodynamics of...

Continuous 5-fluorouracil infusion plus long acting Octreotide in advanced well differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network.
BMC Cancer, 11/09/09 Relevance Score: 87%

High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors
Anticancer Research, 11/11/09 Relevance Score: 85%

Treatment of Malignant Enterovesical Fistula with Octreotide
Journal of Palliative Medicine, 10/12/09 Relevance Score: 85%

The Efficacy of Octreotide LAR as Firstline Therapy for Patients with Newly Diagnosed Acromegaly is Independent of Tumor Extension: Predictive Factors of Tumor and Biochemical Response
Hormone and Metabolic Research, 10/06/09 Relevance Score: 85%

Resolution of chyloperitoneum in a preterm with octreotide, diet and cessation of dialysis
Pediatric Nephrology, 11/16/09 Relevance Score: 84%